Quectel Unveils a Series of New High Performing 5G, GNSS and 5-in-1 Combo Antennas
27.3.2024 16:00:00 EET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has made further additions to its comprehensive range of antennas for IoT devices and deployments. The latest launches include the YEMN016AA and YEMN017AA 5G 5-in-1 combination antennas, the YECN001J1A and YECT000WBA external 5G antennas and the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas.
“We are thrilled to expand our product line with antennas that offer superior performance and meet the unique needs of our IoT customers,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Quectel consistently enhances its diverse portfolio to precisely address the unique requirements of our clients' deployments and applications, offering unparalleled performance and adaptability, and these antennas add to that portfolio.”
The YEMN016AA is a 5G and global navigation satellite systems (GNSS) 5-in-1 antenna measuring 204.4mm x 86.7mm x 32mm. This ultra-wide-band 5G/4G antenna provides broad coverage from 600–6,000MHz whilst offering backward-compatibility to support 3G and 2G networks as well as LTE Cat-M and narrowband IoT (NB-IoT). The antenna is available with connection via five cable lengths from 300–5,000 mm, terminated with SMA connectors. This low profile, screw mount omnidirectional antenna, ideal for applications where the antenna is required to be discrete, is easy to install with maximum durability assured thanks to its IP69K PC KIBILAC® ASA enclosure. It is compatible with Quectel's RM520x Series modules.
The Quectel YEMN017AA is a 5G screw mount 5-in-1 antenna puck optimized for 5G and 4G networks. With a diameter of 103.5mm and height of 42.5mm, the antenna can integrate a variety of antennas, such as 5G, 4G, GNSS and Wi-Fi antennas. Available with multiple mounting options including screw, pole, wall, magnetic, adhesive and others, the antenna box supports multiple connector types and cable lengths and is designed to offer a more flexible and reliable high-performance antenna for outdoor applications.
Quectel has also added the YECN001J1A and YECT000WBA external 5G antennas to its portfolio. Both antennas cover the 5G NR Sub-6 GHz frequency bands and are compatible with 4G, 3G, 2G and LPWA bands. Featuring high efficiency and gain, both offer an ideal omni-directional antenna solution to ensure high-speed data transmission. Ideal for a diversity of wireless communication devices such as routers, outdoor equipment and real-time monitoring equipment, the antennas feature a diameter of 40.6mm and height of 104mm. The antennas are both RoHS and REACH compliant and Quectel offers flexible installation with custom cable length and connector options.
For users prioritizing GNSS, Quectel has introduced the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas. Operating in the 1164-1189MHz and 1559-1606MHz frequency bands these antennas measure 62mm x 56mm x 23mm. The antennas support different installation or connection methods such as screw mount, adhesive mount, magnetic mount, internal cable, and external SMA. Customized connector types and cable lengths are provided according to requirements.
In common with all Quectel antennas, Quectel provides comprehensive antenna design support such as simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. In addition, Quectel antennas can be pre-integrated with Quectel’s vast range of modules.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327795741/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom